Skip to main content
OTCMKTS:IRBS

IR Biosciences Competitors

$0.0002
0.00 (0.00 %)
(As of 05/17/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.00
$0.00
50-Day Range N/A
52-Week Range
$0.00
$0.09
VolumeN/A
Average Volume103,593 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Beta19.66

Competitors

IR Biosciences (OTCMKTS:IRBS) Vs. ACUS, AFFY, ARYX, AHROQ, CBPI, and CDSG

Should you be buying IRBS stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to IR Biosciences, including Acusphere (ACUS), Affymax (AFFY), ARYx Therapeutics (ARYX), AtheroNova (AHROQ), China Botanic Pharmaceutical (CBPI), and China Dongsheng International (CDSG).

Acusphere (OTCMKTS:ACUS) and IR Biosciences (OTCMKTS:IRBS) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, risk and institutional ownership.

Profitability

This table compares Acusphere and IR Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AcusphereN/AN/AN/A
IR BiosciencesN/AN/AN/A

Volatility & Risk

Acusphere has a beta of -0.25, indicating that its share price is 125% less volatile than the S&P 500. Comparatively, IR Biosciences has a beta of 19.66, indicating that its share price is 1,866% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Acusphere and IR Biosciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Acusphere0000N/A
IR Biosciences0000N/A

Valuation & Earnings

This table compares Acusphere and IR Biosciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AcusphereN/AN/AN/AN/AN/A
IR BiosciencesN/AN/AN/AN/AN/A

Summary

IR Biosciences beats Acusphere on 1 of the 1 factors compared between the two stocks.

Affymax (OTCMKTS:AFFY) and IR Biosciences (OTCMKTS:IRBS) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, dividends, risk and institutional ownership.

Valuation and Earnings

This table compares Affymax and IR Biosciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AffymaxN/AN/AN/AN/AN/A
IR BiosciencesN/AN/AN/AN/AN/A

Volatility and Risk

Affymax has a beta of 2.77, indicating that its stock price is 177% more volatile than the S&P 500. Comparatively, IR Biosciences has a beta of 19.66, indicating that its stock price is 1,866% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Affymax and IR Biosciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Affymax0000N/A
IR Biosciences0000N/A

Profitability

This table compares Affymax and IR Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AffymaxN/AN/AN/A
IR BiosciencesN/AN/AN/A

Summary

IR Biosciences beats Affymax on 1 of the 1 factors compared between the two stocks.

IR Biosciences (OTCMKTS:IRBS) and ARYx Therapeutics (OTCMKTS:ARYX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, earnings and institutional ownership.

Valuation and Earnings

This table compares IR Biosciences and ARYx Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IR BiosciencesN/AN/AN/AN/AN/A
ARYx TherapeuticsN/AN/AN/AN/AN/A

Volatility & Risk

IR Biosciences has a beta of 19.66, indicating that its stock price is 1,866% more volatile than the S&P 500. Comparatively, ARYx Therapeutics has a beta of -0.53, indicating that its stock price is 153% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations for IR Biosciences and ARYx Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IR Biosciences0000N/A
ARYx Therapeutics0000N/A

Profitability

This table compares IR Biosciences and ARYx Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IR BiosciencesN/AN/AN/A
ARYx TherapeuticsN/AN/AN/A

Summary

IR Biosciences beats ARYx Therapeutics on 1 of the 1 factors compared between the two stocks.

IR Biosciences (OTCMKTS:IRBS) and AtheroNova (OTCMKTS:AHROQ) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, earnings and institutional ownership.

Profitability

This table compares IR Biosciences and AtheroNova's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IR BiosciencesN/AN/AN/A
AtheroNovaN/AN/AN/A

Volatility & Risk

IR Biosciences has a beta of 19.66, indicating that its stock price is 1,866% more volatile than the S&P 500. Comparatively, AtheroNova has a beta of -8.71, indicating that its stock price is 971% less volatile than the S&P 500.

Valuation and Earnings

This table compares IR Biosciences and AtheroNova's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IR BiosciencesN/AN/AN/AN/AN/A
AtheroNovaN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent recommendations for IR Biosciences and AtheroNova, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IR Biosciences0000N/A
AtheroNova0000N/A

Summary

IR Biosciences beats AtheroNova on 1 of the 1 factors compared between the two stocks.

IR Biosciences (OTCMKTS:IRBS) and China Botanic Pharmaceutical (OTCMKTS:CBPI) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, earnings, institutional ownership and valuation.

Profitability

This table compares IR Biosciences and China Botanic Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IR BiosciencesN/AN/AN/A
China Botanic PharmaceuticalN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings for IR Biosciences and China Botanic Pharmaceutical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IR Biosciences0000N/A
China Botanic Pharmaceutical0000N/A

Volatility and Risk

IR Biosciences has a beta of 19.66, indicating that its share price is 1,866% more volatile than the S&P 500. Comparatively, China Botanic Pharmaceutical has a beta of 17.09, indicating that its share price is 1,609% more volatile than the S&P 500.

Earnings & Valuation

This table compares IR Biosciences and China Botanic Pharmaceutical's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IR BiosciencesN/AN/AN/AN/AN/A
China Botanic PharmaceuticalN/AN/AN/AN/AN/A

Summary

IR Biosciences beats China Botanic Pharmaceutical on 1 of the 1 factors compared between the two stocks.

China Dongsheng International (OTCMKTS:CDSG) and IR Biosciences (OTCMKTS:IRBS) are both consumer staples companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, profitability, risk, institutional ownership and analyst recommendations.

Analyst Ratings

This is a breakdown of current ratings and price targets for China Dongsheng International and IR Biosciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
China Dongsheng International0000N/A
IR Biosciences0000N/A

Valuation and Earnings

This table compares China Dongsheng International and IR Biosciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China Dongsheng InternationalN/AN/AN/AN/AN/A
IR BiosciencesN/AN/AN/AN/AN/A

Profitability

This table compares China Dongsheng International and IR Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
China Dongsheng InternationalN/AN/AN/A
IR BiosciencesN/AN/AN/A

Risk & Volatility

China Dongsheng International has a beta of 13.38, meaning that its stock price is 1,238% more volatile than the S&P 500. Comparatively, IR Biosciences has a beta of 19.66, meaning that its stock price is 1,866% more volatile than the S&P 500.

Summary

IR Biosciences beats China Dongsheng International on 1 of the 1 factors compared between the two stocks.


IR Biosciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Acusphere logo
ACUS
Acusphere
0.0$0.05flat$0.00N/A0.00Gap Up
Affymax logo
AFFY
Affymax
0.6$0.08flat$0.00N/A0.00Gap Down
ARYX
ARYx Therapeutics
0.0$0.01flat$0.00N/A0.00
AHROQ
AtheroNova
0.0$0.01flat$0.00N/A0.00
CBPI
China Botanic Pharmaceutical
0.0$0.08flat$0.00N/A0.00Gap Down
China Dongsheng International logo
CDSG
China Dongsheng International
0.3$0.05flat$0.00N/A0.00Gap Down
China Health Industries logo
CHHE
China Health Industries
0.4$0.25flat$0.00$9.93 million4.20Upcoming Earnings
DDXSQ
Diadexus
0.0$0.00flat$0.00N/A0.00
ERBA
ERBA Diagnostics
0.8$0.04flat$0.00N/A0.00
FTCY
Global Future City
0.5$0.00flat$0.00N/A0.00
GLSI
Greenwich LifeSciences
2.0$32.89flat$0.00N/A0.00
HRBR
Harbor Diversified
0.0$1.90flat$0.00$263.61 million0.00Gap Up
IPAH
Interpharm
0.2$0.00flat$0.00N/A0.00
MBVXQ
MabVax Therapeutics
0.0$0.02flat$0.00N/A0.00Gap Down
MYRX
Myrexis
0.5$0.05flat$0.00N/A0.00Gap Down
NNBP
Nanobac Pharmaceuticals
0.0$0.00flat$0.00N/A0.00Gap Down
PARD
Poniard Pharmaceuticals
0.5$0.09flat$0.00N/A0.00
SGTI
Shengtai Pharmaceutical
0.2$0.02flat$0.00N/A0.00
SKBI
Skystar Bio-Pharmaceutical
0.5$0.00flat$0.00N/A0.00
SUWN
Sunwin Stevia International
0.5$0.05flat$0.00$26.09 million0.00
Sycamore Entertainment Group logo
SEGI
Sycamore Entertainment Group
0.3$0.03flat$0.00N/A0.00
SYNI
Synvista Therapeutics
0.0$0.00flat$0.00N/A0.00
TPIY
Tianyin Pharmaceutical
0.6$0.00flat$0.00N/A0.00High Trading Volume
Tibet Pharmaceuticals logo
TBET
Tibet Pharmaceuticals
0.0$0.01flat$0.00N/A0.00High Trading Volume
Gap Down
VOQP
VioQuest Pharmaceuticals
0.0$0.01flat$0.00N/A0.00
This page was last updated on 5/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.